ClinicalTrials.gg
CompletedNCT03468790Updated Oct 11, 2021

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

A Phase 3 interventional study of CMAB007 and Symbicort in Asthma, Allergic, sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd.. Completed at 2 sites in China. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
55th of 182
393 · median 203
Started
2018
with 7 others
Phase 3
47 of 251
13 open now
Registered
74th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 55th largest by enrollment of the 182 interventional ones that give a count, is one of 8 that started in 2018, is one of 47 in phase 3, and was the 74th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a multi-centre, randomized, double-blind,placebo parallel-controlled phase III study to evaluate the efficacy and safety of CMAB007 (recombinant humanized anti-immunoglobulin E(IgE) monoclonal antibody for injection) to treat asthma patients who remain not adequately controlled despite Med/high ICS plus LABA in China. Following a screening period of up to 2 weeks and run-in period of 4 weeks, randomized patients will enter a 24-week treatment period with CMAB007 or placebo. Efficacy and safety will be assessed at 4-week intervals during the treatment period.

Read the detailed description

Approximately 400 asthma patients with an increased serum total IgE level(60-1500 international unit(IU)/ml) and uncontrolled receiving medium to high dose inhaled corticosteroid (ICS) plus long-acting β2-agonist(LABA) will be randomised in about 43 sites in China. They will be administered CMAB007 or placebo at a ratio of 2:1 for 24 weeks. During the whole study, all subjects will be on regularly fixed combination of med/high ICS and LABA (budesonide and formoterol fumarate powder for inhalation or salmeterol xinafoate and fluticasone propionate powder for inhalation). They should complete PEF measurement and patient diary daily and be assessed every 4 weeks. Spirometry, questionnaires, laboratory tests and so on will be performed. At selected sites, about 45 patients will be enrolled in a sub-study to assess the pharmacokinetic and pharmacodynamic characterises of CMAB007. Anti-drug antibody (ADA) will be sampled at V1, V2 and V7 too.

03

Conditions studied

  • Asthma, Allergic

Browse trials for

04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated prior to any study assessment;
  2. Age 15-75 years inclusive, female or male;
  3. Diagnosed as asthma according to the guideline for the prevention and treatment of bronchial asthma in China (version 2016), with duration for more than 1 years;
  4. Have had at least one severe asthma exacerbations(requiring systemic use) in the previous one year;
  5. At screening, serum total IgE level 60-1500IU/ml and body weight 20-150kg.
  6. Receiving seretide(fluticasone>250ug/day) or symbicort(budesonide>400ug/day) for at least 3 months and stable dose for at least 4 weeks prior to screening. Asthma symptom control level is still partly controlled or uncontrolled. Detailed drugs and usage are one of the following: Seretide 50/250ug 1 inhalation bid;Seretide 50/500ug 1 inhalation bid;Symbicort 160/4.5ug 2 inhalations bid or Symbicort 320/9ug 1 inhalation bid.
  7. None of other asthma controller medications other than seretide or symbicort including systemic steroid, leukotriene modifiers, theophylline, histamine1 receptor blockers, anticholinergic drugs, traditional Chinese medicine and so on have been used 2 weeks prior to screening.
  8. At screening, \< 80% of the predicted normal value.
  9. At screening, laboratory tests results should meet all of the following: ≥80g/l;3*10\^9/l≤white blood cell≤10*10\^9/l;≥75*10\^9/l;liver function(glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase and total )≤2* value;renal function≤1.5*upper limit of normal value.
  10. At screening, pregnant test is negative,or not lactating, for women of . Effective methods of will be maintained throughout the study and 6 months after the study.
  11. Can understand and complete questionnaires correctly, complete PEF and patient diary correctly, and be followed up according to scheduled table.

Exclusion criteria

Exclusion Criteria:

  1. History of critical asthma exacerbations,such as tracheal intubation or intensive care unit admission.
  2. Currently smoker, or a former smoker with a smoking history > 10 pack-years(defined as the number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked).
  3. Have elevated serum IgE levels for other causes other than allergens, such as parasite infections, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome and so on.
  4. Desensitization therapy or agents such as cyclosporine, methotrexate and gold preparation during 3 months prior to screening.
  5. Biological agents such as monoclonal antibody including biological drugs during 6 months prior to screening.
  6. Vaccinated live/attenuated virus or bacterial vaccines, or intravenous used immunoglobulin G, during 4 weeks prior to screening.
  7. History of bronchial thermoplasty for asthma during 12 months prior to screening.
  8. Use of any anti-IgE monoclonal antibody including Xolair for asthma during 12 months prior to screening.
  9. Respiratory infections(such as pneumonia,upper respiratory tract infection,etc)or large surgeries during 4 weeks prior to screening.
  10. Combined with other pulmonary diseases, such as , bronchiectasis, pulmonary interstitial fibrosis, etc.
  11. History of other than squamous cell carcinoma or basal cell carcinoma of the skin and carcinoma in situs of cervix with complete excision and no evidence of recurrences.
  12. Acquired immune deficiency syndrome or infection patients.
  13. History of malignant or proliferative diseases of the lymphatic system such as lymphoma, or there are symptoms and signs indicating lymphatic proliferative diseases, or splenomegaly (≥2cm under the ribs).
  14. With uncontrolled hypertension(systolic pressure ≥160 or diastolic pressure ≥100 in millimeters of mercury) at screening.
  15. With severe, progressive or uncontrolled hepatic, renal, gastrointestinal, cardio-cerebral vascular, hematopoietic,genitourinary, endocrine, nervous and immunological medical conditions, or other conditions that investigators think the patient not suitable for this study.
  16. Have a history of drug or alcohol abuse or poor compliance of drugs.
  17. With known to human immunoglobulin, anti-IgE monoclonal antibody for injection or components.
  18. Have attended other clinical trials of investigational drugs, or within 30 days or 5 half-lives of enrollment, whichever is longer.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    CMAB007 + Seretide/Symbicort + Ventolin

    CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.

    Drug: CMAB007 · Drug: Symbicort · Drug: Seretide · Drug: Ventolin

  • Placebo comparator
    Placebo + Seretide/Symbicort + Ventolin

    Placebo is without active components of the study drug and used as same as the study drug.

    Drug: Symbicort · Drug: Seretide · Drug: Ventolin · Drug: placebo

Interventions

  • the study drug

    Also known as: recombinant humanized anti-IgE monoclonal antibody

  • DrugSymbicort

    asthma-controlled drug

    Also known as: budesonide and formoterol fumarate powder for inhalation

  • DrugSeretide

    asthma-controlled drug

    Also known as: salmeterol xinafoate and fluticasone propionate

  • asthma rescue drug

    Also known as: Salbutamol sulphate aerosol

  • Drugplacebo

    No active components

06

What researchers measure

Primary outcomes

  1. the mean number of asthma exacerbations per patient during the 24-week treatment period

    Asthma exacerbation is defined by a worsening of asthma symptoms resulting in: 1.out-planned outpatient visit; 2.use of systemic and/or nebulized inhaled corticosteroids; 3.emergency room visit; 4. hospitalization.

    Time frame: from baseline(0 week) to 24 weeks

Secondary outcomes

  1. the proportion of patients with asthma exacerbations during the 24-week treatment period

    the number of patients with at least one exacerbations divided by the total number of patients.

    Time frame: from baseline(0 week) to 24 weeks

  2. time to the first asthma exacerbation during treatment period

    the time from baseline to the first asthma exacerbation

    Time frame: from baseline(0 week) to 24 weeks

  3. change from baseline in asthma symptom scores(daytime, nocturnal and total) over the 24-week treatment period

    mean asthma symptom scores(daytime, nocturnal and total): (pre-treatment - post-treatment)/pre-treatment \*100%

    Time frame: from baseline(0 week) to 24 weeks

  4. change from baseline in Asthma Control Test(ACT) over the 24-week treatment period

    ACT total score: (pre-treatment - post-treatment)/pre-treatment \*100%

    Time frame: from baseline(0 week) to 24 weeks

  5. change from baseline in Asthma Quality of Life Questionnaire(AQLQ) over the 24-week treatment period

    AQLQ total score and threshold score: (pre-treatment - post-treatment)/pre-treatment \*100%

    Time frame: from baseline(0 week) to 24 weeks

  6. investigator's and patient's Global Evaluation of Treatment Effectiveness(GETE) over 16 and 24-week treatment period

    GETE score at week 16 and 24

    Time frame: from baseline(0 week) to 16 and 24 weeks

  7. change from baseline in rescue medication use over the 24-week treatment period

    mean rescue medication use(puff/day): (pre-treatment - post-treatment)/pre-treatment \*100%

    Time frame: from baseline(0 week) to 24 weeks

  8. change from baseline in lung function parameters(FEV1,FVC and FEV1/FVC) over the 24-week treatment period

    FEV1,FVC and FEV1/FVC values: (post-treatment - pre-treatment)/pre-treatment \*100%

    Time frame: from baseline(0 week) to 24 weeks

  9. change from baseline in mean peak expiratory flow(PEF) over the 24-week treatment period

    mean PEF value: (post-treatment - pre-treatment)/pre-treatment \*100%

    Time frame: from baseline(0 week) to 24 weeks

07

Study locations

2 sites
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jan 2021, 32 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 19, 2018
StartActual
May 9, 2018
Primary completionActual
Jan 12, 2021
CompletionActual
Mar 9, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03468790
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 19, 2018
Start date
May 9, 2018
Primary completion
Jan 12, 2021
Completion
Mar 9, 2021
Last update
Oct 11, 2021

Study contacts

Nanshan Zhong, M.D.
principal investigator · The First Affiliated Hospital of Guangzhou Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CMAB007

Start the discussion